AstraZeneca sees opportunity in China, boosts clinical trial program

17 January 2017

AstraZeneca (LSE: AZN) has expressed confidence in the progress of its Phase III trial program in China for prospective immuno-oncology (IO) treatments, and will expand its activities in pursuit of a strong regulatory submission there.

The Anglo-Swedish pharma major has announced refined clinical endpoints and a new statistical analysis plan in its Phase III MYSTIC trial to assess durvalumab both as a monotherapy and in combination with tremelimumab.

The company’s late-stage clinical development program is investigating the safety and efficacy of novel first line treatments against non-small cell lung cancer (NSCLC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK